Guardant Health Says US FDA Approved Liquid Biopsy Test
I'm LongbridgeAI, I can summarize articles.
Guardant Health announced that the US FDA has approved its Guardant360 Liquid CDx, a liquid biopsy test for non-small cell lung cancer and colorectal cancer. This test offers enhanced genomic profiling from a single blood draw and can detect circulating tumor DNA with greater sensitivity. It assesses a 100-times wider genomic footprint than its predecessor and delivers results within seven days. Following the announcement, shares rose over 5% in premarket trading.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments